Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:FLNA NASDAQ:SNSE NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.52+0.4%$6.25$3.25▼$13.50$70.55M0.91319,999 shs11,870 shsFLNACassava Sciences$1.32$1.49$1.16▼$4.98$63.77M-0.71553,706 shs17,983 shsSNSESensei Biotherapeutics$12.40+8.7%$24.13$5.60▼$36.76$16.62M-0.25193,944 shs8,676 shsUPXIUpexi$0.87+0.9%$1.23$0.54▼$13.37$61.20M-0.354.44 million shs663,729 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-1.26%-4.51%-15.38%-7.09%+29.11%FLNACassava Sciences-7.04%-2.94%+3.13%-44.54%-39.17%SNSESensei Biotherapeutics-9.66%-28.01%-44.96%-63.43%+63.47%UPXIUpexi-3.48%-14.85%-41.50%-7.57%-92.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.52+0.4%$6.25$3.25▼$13.50$70.55M0.91319,999 shs11,870 shsFLNACassava Sciences$1.32$1.49$1.16▼$4.98$63.77M-0.71553,706 shs17,983 shsSNSESensei Biotherapeutics$12.40+8.7%$24.13$5.60▼$36.76$16.62M-0.25193,944 shs8,676 shsUPXIUpexi$0.87+0.9%$1.23$0.54▼$13.37$61.20M-0.354.44 million shs663,729 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-1.26%-4.51%-15.38%-7.09%+29.11%FLNACassava Sciences-7.04%-2.94%+3.13%-44.54%-39.17%SNSESensei Biotherapeutics-9.66%-28.01%-44.96%-63.43%+63.47%UPXIUpexi-3.48%-14.85%-41.50%-7.57%-92.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 2.71Moderate Buy$33.25502.36% UpsideFLNACassava Sciences 2.00Hold$5.00278.79% UpsideSNSESensei Biotherapeutics 2.43Hold$48.00287.10% UpsideUPXIUpexi 2.67Moderate Buy$8.33860.06% UpsideCurrent Analyst Ratings BreakdownLatest SNSE, FLNA, CLNN, and UPXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SNSESensei Biotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/8/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/22/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.005/14/2026CLNNClene Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$200K352.73N/AN/A($1.62) per share-3.41FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/AUPXIUpexi$15.81M3.86N/AN/A$1.01 per share0.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/ASNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)UPXIUpexi-$13.68M-$0.62N/AN/AN/A-874.00%-66.70%-19.56%N/ALatest SNSE, FLNA, CLNN, and UPXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/12/2026Q3 2026UPXIUpexi-$0.20-$1.67-$1.47-$1.67$2.90 million$1.05 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million3/12/2026Q4 2025FLNACassava Sciences-$0.30-$0.26+$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.941.93FLNACassava SciencesN/A2.192.19SNSESensei BiotherapeuticsN/A14.3914.39UPXIUpexi2.961.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%FLNACassava Sciences38.05%SNSESensei Biotherapeutics10.50%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCLNNClene28.30%FLNACassava Sciences4.60%SNSESensei Biotherapeutics7.00%UPXIUpexi9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10012.78 million9.16 millionNo DataFLNACassava Sciences2048.31 million46.09 millionOptionableSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableUPXIUpexi13070.26 million63.94 millionOptionableSNSE, FLNA, CLNN, and UPXI HeadlinesRecent News About These CompaniesUPXI Share News TodayMay 19, 2026 | uk.investing.comUpexi (UPXI) Stock Forecast & Price TargetMay 15, 2026 | investing.comUpexi Stock Short Interest Report | NASDAQ:UPXI | BenzingaMay 15, 2026 | benzinga.comUpexi (UPXI) Q3 2026 Earnings TranscriptMay 15, 2026 | fool.comUpexi, Inc. Earnings Call Highlights Crypto-Fueled VolatilityMay 13, 2026 | tipranks.comUpexi Net Loss Balloons to $109 Million on Solana Treasury MarkdownMay 13, 2026 | finance.yahoo.comUpexi Q3 Earnings Call HighlightsMay 12, 2026 | marketbeat.comUpexi Reports Fiscal Third Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comUpexi Q3 2026 earnings previewMay 11, 2026 | msn.comUpexi to Present at the LD Micro Invitational XVI Conference on May 17-19May 7, 2026 | globenewswire.comUpexi Provides Periodic Update to its Share Repurchase ProgramMay 6, 2026 | globenewswire.comUpexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ETMay 5, 2026 | globenewswire.comUpexi to Participate in the Scottsdale Capital Event on April 10-12March 31, 2026 | globenewswire.comUpexi to Participate in Upcoming March Investor ConferencesMarch 3, 2026 | globenewswire.comUpexi Earnings Call: Growth Surges, Losses MountFebruary 15, 2026 | tipranks.comInsiders' US$4.22m Investments In Red Following Upexi's US$18m Dip In Market ValueFebruary 14, 2026 | finance.yahoo.comUpexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset ChallengesFebruary 13, 2026 | uk.finance.yahoo.comUpexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset ChallengesFebruary 13, 2026 | uk.finance.yahoo.comUpexi, Inc. (NASDAQ: UPXI) Q2 2026 earnings call transcriptFebruary 11, 2026 | msn.comUpexi (UPXI) Q2 2026 Earnings Call TranscriptFebruary 11, 2026 | finance.yahoo.comUpexi targets yield growth and capital market innovation amid Solana-driven volatilityFebruary 10, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNSE, FLNA, CLNN, and UPXI Company DescriptionsClene NASDAQ:CLNN$5.53 +0.03 (+0.62%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Cassava Sciences NASDAQ:FLNA$1.32 0.00 (0.00%) As of 10:33 AM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.Sensei Biotherapeutics NASDAQ:SNSE$12.26 +0.85 (+7.47%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Upexi NASDAQ:UPXI$0.87 +0.01 (+0.81%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align 2 Ways to Play the QXO/TopBuild Deal The “Duck Stock” Keeps Quietly Making Money for Shareholders Everpure: AI Storage Uncertainty Overshadows Breakneck Growth As Shares Fall, Analyst Are Boosting their Broadcom Price Targets This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
